Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)12.14bn
- Net income in MXN947.54m
- Incorporated1996
- Employees1.05k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeMEXICO, D.F. 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttp://www.genommalab.com/mx/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotoscana Investments SA | 3.49bn | 218.09m | 4.29bn | 679.00 | 19.89 | 1.22 | 11.40 | 1.23 | 0.443 | 0.443 | 7.09 | 7.22 | 0.6177 | 2.22 | 2.71 | 1,065,100.00 | 3.85 | -- | 5.15 | -- | 48.95 | -- | 6.24 | -- | 1.36 | 3.95 | 0.2302 | -- | 0.4177 | -- | 274.77 | -- | -- | -- |
| Ouro Fino Saude Animal Participacoes SA | 2.77bn | 186.79m | 9.56bn | 1.01k | 51.20 | 4.31 | 31.56 | 3.45 | 0.7471 | 0.7471 | 11.09 | 8.87 | 0.7018 | 1.69 | 4.07 | -- | 4.73 | -- | 6.09 | -- | 51.16 | -- | 6.74 | -- | 1.18 | -- | 0.3868 | -- | 16.61 | 8.94 | 80.66 | 5.02 | -1.69 | -- |
| Genomma Lab Internacional SAB de CV | 12.14bn | 947.54m | 20.65bn | 1.05k | 22.08 | 2.49 | 19.23 | 1.70 | 0.8922 | 0.8922 | 11.28 | 7.92 | 0.6669 | 2.49 | 3.99 | 12,364,280.00 | 5.20 | 1.39 | 6.93 | 1.95 | 63.69 | 67.22 | 7.80 | 2.23 | 1.44 | 4.56 | 0.4295 | 0.00 | -2.35 | 0.7522 | -13.27 | -8.74 | -11.15 | -- |
| Hypera SA | 15.26bn | 5.80bn | 101.96bn | 8.79k | 17.69 | 2.54 | 16.13 | 6.68 | 1.97 | 1.94 | 5.16 | 13.71 | 0.3123 | 1.82 | 2.54 | 374,838.50 | 11.88 | 5.71 | 13.58 | 6.99 | 65.85 | 73.78 | 38.02 | 22.11 | 2.26 | -- | 0.059 | 40.75 | 6.41 | -2.65 | 2.15 | 34.41 | -1.78 | 35.92 |
| Holder | Shares | % Held |
|---|---|---|
| Massachusetts Financial Services Co.as of 30 Sep 2019 | 52.82m | 5.04% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2019 | 51.71m | 4.93% |
| Fidelity Management & Research Co.as of 30 Sep 2019 | 45.28m | 4.32% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2019 | 35.95m | 3.43% |
| The Vanguard Group, Inc.as of 30 Sep 2019 | 25.69m | 2.45% |
| Invesco Canada Ltd.as of 30 Jun 2019 | 23.41m | 2.23% |
| Dimensional Fund Advisors LPas of 07 Nov 2019 | 19.45m | 1.86% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 07 Nov 2019 | 18.69m | 1.78% |
| BlackRock Fund Advisorsas of 07 Nov 2019 | 12.85m | 1.23% |
| Baillie Gifford & Co.as of 30 Jun 2019 | 6.62m | 0.63% |
